home / stock / eras / eras short
Short Information | Erasca Inc. (NASDAQ:ERAS)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 5,773,126 |
Total Actual Volume | 45,040,260 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 288,656 |
Average Short Percentage | 16.23% |
Is there a ERAS Short Squeeze or Breakout about to happen?
See the ERAS Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $2.43 | $2.32 | $2.51 | $2.32 | 1,228,754 | 231,766 | 18.86% |
07-01-2024 | $2.34 | $2.44 | $2.47 | $2.335 | 10,546,332 | 245,049 | 2.32% |
06-28-2024 | $2.31 | $2.36 | $2.395 | $2.14 | 6,893,221 | 284,199 | 4.12% |
06-27-2024 | $2.21 | $2.31 | $2.37 | $2.17 | 3,181,840 | 769,167 | 24.17% |
06-26-2024 | $2.06 | $2.2 | $2.24 | $2.01 | 3,262,225 | 880,685 | 27% |
06-25-2024 | $2.11 | $2.08 | $2.24 | $2.07 | 2,829,831 | 570,915 | 20.17% |
06-24-2024 | $2.12 | $2.16 | $2.19 | $2.09 | 2,998,878 | 500,490 | 16.69% |
06-21-2024 | $2.04 | $2.11 | $2.14 | $2.015 | 2,824,283 | 448,178 | 15.87% |
06-20-2024 | $2.04 | $2.03 | $2.06 | $2.01 | 599,525 | 134,236 | 22.39% |
06-18-2024 | $1.99 | $2.04 | $2.07 | $1.96 | 858,168 | 117,344 | 13.67% |
06-17-2024 | $2.13 | $2 | $2.1368 | $1.96 | 1,185,319 | 182,710 | 15.41% |
06-14-2024 | $2.16 | $2.17 | $2.24 | $2.15 | 672,203 | 111,378 | 16.57% |
06-13-2024 | $2.23 | $2.18 | $2.29 | $2.17 | 933,887 | 55,973 | 5.99% |
06-12-2024 | $2.33 | $2.22 | $2.38 | $2.21 | 761,743 | 138,675 | 18.2% |
06-11-2024 | $2.24 | $2.25 | $2.26 | $2.12 | 753,433 | 144,411 | 19.17% |
06-10-2024 | $2.35 | $2.28 | $2.37 | $2.25 | 736,539 | 193,700 | 26.3% |
06-07-2024 | $2.32 | $2.375 | $2.41 | $2.31 | 495,295 | 45,082 | 9.1% |
06-06-2024 | $2.61 | $2.355 | $2.62 | $2.345 | 654,388 | 87,197 | 13.32% |
06-05-2024 | $2.62 | $2.62 | $2.7 | $2.591 | 2,028,767 | 328,404 | 16.19% |
06-04-2024 | $2.56 | $2.61 | $2.62 | $2.5 | 1,595,629 | 303,567 | 19.02% |
News, Short Squeeze, Breakout and More Instantly...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...